RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine : A Randomized, Double-blind, Placebo-controlled, Cross-over Trial - RENACTIF

ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE0 个研究点目标入组 40 人开始时间: 2018年10月25日最近更新: 2021年7月5日

适应症

试验速览

暂无简介。

•Adult subjects of both sexes aged 18 years and over
•Affiliated subjects or beneficiaries of a social security scheme
•Hemodialysis patients regardless of the etiology of their renal insufficiency for more than three months on a cycle of three sessions per week
•Hemodialysis patients at least four hours per dialysis session
•Patients with a weight of more than 40kg
•Subjects capable of giving informed consent, agreeing to participate in the study and having signed a consent
•Patient able to understand a written questionnaire
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Pregnant or lactating women
•Persons deprived of their liberty or hospitalized without consent
•Majors under legal protection or unable to express their consent Possibility of recovery of renal function
•Chronic progressive infection that may affect their thrombotic risk: progressive neoplasia, anticoagulant treatment prescribed for less than 1 month
•Patients with a weight under 40 kg
•Patient not able to express his consent
•Patient taking AVK-type oral anticoagulants outside anticoagulation during the session.
•Patient with a known allergy to the active molecule or an excipient

发起方